Overview

Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway

Status:
Terminated

Trial end date:
2021-04-27

Target enrollment:

Participant gender:

Summary

The investigators propose a phase II study to evaluate the efficacy of carboplatin monotherapy in the tumor subgroup of metastatic castration-resistant prostatic carcinomas with somatic abnormality in the Homologous Recombination (HR) pathway. This study may also better characterize the molecular abnormalities of tumors required for the carboplatin response

Phase:

Phase 2

Details

Lead Sponsor:

Centre Francois Baclesse

Collaborators:

GIRCI (French Interregional Group of Clinical Research and Innovation)
Ligue Contre le Cancer (French association Against Cancer)

Treatments:

Carboplatin